<DOC>
	<DOCNO>NCT02332005</DOCNO>
	<brief_summary>An interventional study investigate efficacy safety diepalrestat ( BNV-222 ) diabetic patient diabetic peripheral neuropathy . Subjects receive twice daily oral dose diepalrestat , aldose reductase inhibitor , placebo investigate effect motor nerve conduction velocity ( MNCV ) symptomatic clinical response 12 month treatment . Subjects assess screen baseline , office visit every 12 week , total 6 visit . The study explore double-blind fashion , effect two dos diepalrestat , 150 300 mg , reduce loss nerve conduction velocity expect demonstrated group randomize placebo treatment 12 month .</brief_summary>
	<brief_title>12-Month Efficacy Safety Diepalrestat Adults With Diabetic Peripheral Neuropathy , DB , Placebo-Controlled Study</brief_title>
	<detailed_description>This 12 month double-blind , randomize , placebo-controlled , parallel group efficacy safety study enroll 400 adult diabetic subject diabetic peripheral neuropathy ( DPN ) investigate effect diepalrestat ( BNV-222 ) 150 mg , 300 mg , placebo MNCV patient ' perception nerve function 12 month measure VAS scale composite clinical outcome patient report scale evaluate numbness , tingle , cramp , paresthesiae , hyperesthesia , coldness , weakness spontaneous pain perception upper low extremity , effect measure nerve motor sensory conduction . Subjects assess screen baseline , office visit every 12 week , total 6 visit . Subjects assess test motor nerve conduction velocity assessment office visit . A subgroup 24 patient select pharmacokinetic ( PK ) test 48 hour additional blood draw Day 7 14 . This study investigate ability diepalrestat reduce ongoing deterioration nerve function hallmark DPN process .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Choline</mesh_term>
	<criteria>Patients type 1 type 2 diabetes mellitus control oral parenteral hypoglycemic agent diet . Patients diabetes stable control ( HbA1C â‰¤ 10 % ) new symptom associate diabetes within previous 3 month . Patients diagnose neuropathy abnormality 2 3 category ( sign , symptom , objective test nerve conduction study quantitative sensory threshold testing ) . Patients pain medication ( prescribed analgesic ) , stable least 3 month study entry pain treatment naive . Patients least mild painful symptom diabetic neuropathy least 1 year duration , long 10 year duration . Able withstand fundus evaluation ophthalmology test A condition would preclude patient participation study opinion investigator , e.g. , unstable medical status include glycemic control blood pressure . Any neurological disorder may confound assessment diabetic peripheral neuropathy radiculopathies . multiple sclerosis , myelopathies . Ongoing severe peripheral arterial disease , skin ulcer , amputation low extremity . Neuropathy finding due follow : alcohol abuse , liver renal disease , toxic exposure , endocrine , metabolic nutritional disorder , inflammatory disease , monoclonal gammopathy . Patients absent peroneal nerve response . Other pain may confound assessment neuropathic pain . Previous participation study investigational drug within 1 month precede Day 0 ( exclude vitamin mineral</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>